Yukon, 1 of 3 Canadian territories, announced that it will implement a biosimilars switching policy, following Newfoundland and Labrador’s announcement to move forward with a similar policy earlier this week.
The government of Yukon announced that it will implement a biosimilars “switching” or transitioning policy, the tenth Canadian jurisdiction and the second territory to do so.
“Biosimilars Canada and its member companies congratulate Health and Social Services Minister Tracy-Anne McPhee and the Yukon Government for implementing a biosimilars switching policy to help support the long-term sustainability of its drug programs and healthcare system,” said Jim Keon, President of Biosimilars Canada, in a statement.
Initially, the policy will only apply to adalimumab biosimilars referencing Humira and insulin glargine biosimilars referencing Lantus. However, it will be expanded to include additional biologics in the future.
The implementation of the policy was recommended by the Putting People First report, which was adopted by the Yukon government in August 2020. The report aimed to transform the territory’s health and social services system.
“Biosimilars are safe, effective, and low-cost drugs used to manage chronic and autoimmune diseases. By enhancing our public drug plan with biosimilars, we are strengthening access to safe and affordable medication while also supporting the sustainability of our healthcare system. This transition aligns the Yukon with other jurisdictions and is another step in achieving our commitments in Putting People First,” said Tracy-Anne McPhee, in a statement from the territory.
The Yukon follows in the footsteps of Newfoundland and Labrador, British Columbia, Nova Scotia, New Brunswick, Saskatchewan, Quebec, the Northwest Territories, Alberta, and Ontario. Newfoundland and Labrador announced its switching policy earlier this week.
The topic of switching or transitioning patients from a reference product to a biosimilar has raised concerns about whether product transitions will alter safety or efficacy outcomes. However, no province with a switching policy has experienced impacts on clinical outcomes and both the European Union and United Kingdom have declared all biosimilars as interchangeable with their reference products.
In its statement, the Yukon government assured that patients who are currently treated with Humira or Lantus will be notified by a health care provider that they will transition to a biosimilar. Yukoners enrolled in the territory’s public health plan will have 6 months to work with their provider to make the transition and maintain coverage.
“Yukon doctors see sustainability of the health care system as a key part of ensuring that Yukoners receive the best health care possible. Incorporating biosimilars into these publicly administered drug and benefit programs is part of ensuring equitable high-quality health care into the future,” noted Alex Kmet, MD, president of the Yukon Medical Association, in the Yukon government's statement.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.